Vitamin D supplementation in multiple sclerosis – Can be done something more?

To the Editor,

In a recently published article by Berezowska et al. [1], they conclude that vitamin D supplementation may be a promising treatment for multiple sclerosis (MS), and represents a reliable background for further exploration of potential benefit regarding clinical improvements. Likewise, they add that a high dose vitamin D supplement intervention may contribute to bettering of physiological mechanisms, especially if baseline plasma levels are at the lower end of normal [1]. Häusler and Weber [2] review the vitamin D potentially immune modulating mechanisms, followed by a summary of current and ongoing clinical trials, intended to assess whether vitamin D supplementation positively influences the outcome of central nervous system (CNS) demyelinating disease. However, in this article, it is underscored the fact that high doses of vitamin D could have negative effects in CNS demyelinating disease via T cell-stimulating effect of secondary hypercalcemia [2]. Similar precautionary conclusions have been pointed out by other authors [1,3–6]. Although it has been described that following oral vitamin D supplementation, patients with MS have a lesser average increase in serum levels of 25-hydroxy-vitamin D (25-OH-D) than healthy individuals having similar starting concentrations [7], in MS patients vitamin D is usually administered in modest daily doses on the order of 1000–3000 IU in association with different disease-modifying therapies. This vitamin D supplementation is increasingly used, providing an added beneficial effect to patients [8].

Frequently, the vitamin D undesirable effects found by Fragoso et al. [9] in some MS patients treated with 8000–150,000 IU/day (median 100,000 IU/day) are highlighted; nevertheless, these authors do not indicate what dosing procedure and clinical follow-up had been done in the patients included in this study, and what preventive measures had been taken to avoid the possible side effects of high doses of vitamin D. Other comments about the data and conclusions provided by Fragoso et al. [9] can be seen in the paper of Kimball et al. [10]. Very possibly, the fear to a considered inevitable development of toxic effects, may explain the little attention awakened by some early studies, any published more than eighty years ago [11,12], on the possible treatment of autoimmune diseases, concretely rheumatoid arthritis, with massive doses of vitamin D.

Vitamin D is a powerful regulator of the immune system activity and, in accordance with the neurologist CG Coimbra from the University of Sao Paulo in Brazil, most patients with autoimmune diseases have an increased resistance to the immunomodulatory effects of vitamin D, mainly due to genetic polymorphisms, which requires the administration of massive doses of this prohormone to be clinically effective. It may be interesting to note here, that Henderson et al. [13] have recently described the case of a woman with absence of circulating vitamin D-binding protein (VDBP), presenting a severe deficiency of vitamin D that did not respond to supplementation. This congenital deficiency of VDBP resulted in normocalcemia and mild disruption of bone metabolism, however, it was accompanied by a severe autoimmune disease (debilitating ankylosing spondylitis).

From years ago, the so-called “Coimbra protocol” with very high daily doses of vitamin D3 (initial dosage ~1000 IU/kg of weight) has been used in America and Europe for the treatment of MS (more than 30,000 patients) and other autoimmune diseases. The clinical results seem to be good, and the patients themselves treated by Coimbra in Sao Paulo, or by one of the doctors accredited to follow this protocol all over the world [14], recommend this therapeutic protocol with insistence and enthusiasm in their facebook groups [15] and in the books telling his own clinical history [16,17]. According to these patients, with MS and other autoimmune disorders, “we constituted the best clinical trial for the Coimbra protocol validation”. Currently, some articles on this subject have been published [18,19], and a recent study conducted in Brazil, shows that MS patients have a high degree of satisfaction with the vitamin D treatment, whether exclusive or complementary [20].

The Coimbrás protocol for autoimmune diseases treatment has not just been recognized, but neither evaluated, in the academic media. It is argued that are necessary more studies to determine the suitable vitamin D dosage, and perform protocolized clinical follow-up, to avoid undesirable toxic effects as the hypercalcemia with all its possible physiopathological complications. Nevertheless, these issues seem to have been resolved by Coimbra itself. Briefly it may be noted that the daily doses of vitamin D are established and adjusted through the serum parathormone (PTH) levels, and not those of 25-OH-D. Likewise, the patients must follow a diet with calcium restriction, magnesium supplementation, and a daily intake of at least 2.5 L of water, to maintain a urinary calcium concentration below 250 mg/L, for kidney stones and nephrocalcinosis prevention. Another factor of great importance for a good clinical evolution of the patients, is the maintenance of an adequate emotional control, which, depending on the degree of affection, could be achieved in approximately 90–95% of cases. Periodically analytical controls of, at least, serum calcium, phosphorus, ura, creatinine, PTH, and 25-OH-D, and also calcium in 24-hour urine samples, are performed. The biochemical and clinical monitoring of patients treated with this protocol for years, shows that, although they present very high levels of serum 25-OH-D (frequently greater than 1000 ng/mL), with very low PTH values around to the inferior reference limit, do not develop hypercalcemia, hypercalciuria, or other toxic effects due to the massive doses administered of vitamin D. More details on this protocol are available in one of the most prestigious online information sources about vitamin D [21].

Although some studies, such as that of Martinsen and Burian [22], are already underway in different European countries, from here, I invite all those involved in the research and/or treatment of MS and other autoimmune diseases, that, free from prejudices, find out about the true therapeutic possibilities of the Coimbra protocol. Then, we can answer to the question raised by Hawkes et al. [23], if for MS patients, vitamin D is “caviar or a dog’s dinner”.

https://doi.org/10.1016/j.mehy.2019.109256

Received 22 March 2019; Received in revised form 22 May 2019; Accepted 1 June 2019

0306-9877/ © 2019 Published by Elsevier Ltd.
Declaration of Competing Interest

None.

References


Jóse-Carllos Tutor
Grupo de Farmacología, Instituto de Investigación Sanitaria (IDIS), Hospital Clínico Universitario, 15706 Santiago de Compostela, Spain
E-mail address: jcarlostutor@gmail.com.